Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair

A wide diversity of perturbations of the central nervous system (CNS) result in structural damage to the neuroarchitecture and cellular defects, which in turn are accompanied by neurological dysfunction and abortive endogenous neurorepair. Altering intracellular signaling pathways involved in inflammation and immune regulation, neural cell death, axon plasticity and remyelination has shown therapeutic benefit in experimental models of neurological disease and trauma. The second messengers, cyclic adenosine monophosphate (cyclic AMP) and cyclic guanosine monophosphate (cyclic GMP), are two such intracellular signaling targets, the elevation of which has produced beneficial cellular effects within a range of CNS pathologies. The only known negative regulators of cyclic nucleotides are a family of enzymes called phosphodiesterases (PDEs) that hydrolyze cyclic nucleotides into adenosine monophosphate (AMP) or guanylate monophosphate (GMP). Herein, we discuss the structure and physiological function as well as the roles PDEs play in pathological processes of the diseased or injured CNS. Further we review the approaches that have been employed therapeutically in experimental paradigms to block PDE expression or activity and in turn elevate cyclic nucleotide levels to mediate neuroprotection or neurorepair as well as discuss both the translational pathway and current limitations in moving new PDE-targeted therapies to the clinic.

[1]  P. Poole,et al.  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.

[2]  P. Cayé-Thomasen,et al.  Inhibition of phosphodiesterase 3, 4, and 5 induces endolymphatic hydrops in mouse inner ear, as evaluated with repeated 9.4T MRI , 2017, Acta oto-laryngologica.

[3]  N. Plesnila,et al.  Nitric oxide inhalation reduces brain damage, prevents mortality, and improves neurological outcome after subarachnoid hemorrhage by resolving early pial microvasospasms , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  D. Bennett,et al.  Reduced pCREB in Alzheimer's disease prefrontal cortex is reflected in peripheral blood mononuclear cells , 2016, Molecular Psychiatry.

[5]  G. Pearlson,et al.  Does Biology Transcend the Symptom-based Boundaries of Psychosis? , 2016, The Psychiatric clinics of North America.

[6]  D. Pearse,et al.  PDE4B as a microglia target to reduce neuroinflammation , 2016, Glia.

[7]  J. O'Donnell,et al.  Memory enhancement induced by PDE2 knockdown in an Alzheimer's disease model of mice , 2016 .

[8]  P. Holtzheimer,et al.  Deep Brain Stimulation for Depression: An Update , 2016, Current Behavioral Neuroscience Reports.

[9]  R. Mirsky,et al.  The repair Schwann cell and its function in regenerating nerves , 2016, The Journal of physiology.

[10]  P. Fossa,et al.  New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies , 2016, Molecular Diversity.

[11]  Yong Xu,et al.  Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines , 2016, Journal of Neuroinflammation.

[12]  D. Pearse,et al.  Acute Putrescine Supplementation with Schwann Cell Implantation Improves Sensory and Serotonergic Axon Growth and Functional Recovery in Spinal Cord Injured Rats , 2015, Neural plasticity.

[13]  J. Gensel,et al.  Macrophage activation and its role in repair and pathology after spinal cord injury , 2015, Brain Research.

[14]  F. Lezoualc’h,et al.  Exchange protein directly activated by cAMP (EPAC) regulates neuronal polarization through Rap1B , 2016, The FASEB Journal.

[15]  R. Caldwell,et al.  Arginase: an old enzyme with new tricks. , 2015, Trends in pharmacological sciences.

[16]  R. Franco,et al.  Decreased levels of guanosine 3′, 5′‐monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease , 2015, Neuropathology and applied neurobiology.

[17]  T. Palmer,et al.  The future of EPAC-targeted therapies: agonism versus antagonism , 2015, Trends in pharmacological sciences.

[18]  P. Gressens,et al.  Nitric Oxide Pathway and Proliferation of Neural Progenitors in the Neonatal Rat , 2015, Developmental Neuroscience.

[19]  M. Ghosh,et al.  The Interplay between Cyclic AMP, MAPK, and NF-κB Pathways in Response to Proinflammatory Signals in Microglia , 2015, BioMed research international.

[20]  S. Bhatt,et al.  Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy , 2015, Psychopharmacology.

[21]  H. Vinters,et al.  Emerging concepts in Alzheimer's disease. , 2015, Annual review of pathology.

[22]  P. Insel,et al.  Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma , 2015, Proceedings of the National Academy of Sciences.

[23]  O. Baud,et al.  Impact of inhaled nitric oxide on white matter damage in growth-restricted neonatal rats , 2015, Pediatric Research.

[24]  K. Ogita,et al.  Beneficial effect of cilostazol‐mediated neuronal repair following trimethyltin‐induced neuronal loss in the dentate gyrus , 2015, Journal of neuroscience research.

[25]  C. Atkins,et al.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury. , 2014, Current pharmaceutical design.

[26]  P. Heckman,et al.  Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. , 2014, Current pharmaceutical design.

[27]  J. Goldberg,et al.  The role of soluble adenylyl cyclase in neurite outgrowth. , 2014, Biochimica et biophysica acta.

[28]  Diana Boraschi,et al.  From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation , 2014, Front. Immunol..

[29]  Srinath Krishnamurthy,et al.  Active site coupling in PDE:PKA complexes promotes resetting of mammalian cAMP signaling. , 2014, Biophysical journal.

[30]  M. Sitges,et al.  The anti‐seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL‐1β and TNF‐α expression in rat hippocampus , 2014, Journal of neurochemistry.

[31]  Jilly F. Evans,et al.  Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. , 2014, Cellular signalling.

[32]  C. Mathis,et al.  PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition , 2014, Neurobiology of Aging.

[33]  M. Fehlings,et al.  Rho-ROCK inhibition in the treatment of spinal cord injury. , 2014, World neurosurgery.

[34]  S. Tabrizi,et al.  Targets for future clinical trials in Huntington's disease: What's in the pipeline? , 2014, Movement disorders : official journal of the Movement Disorder Society.

[35]  E. Knott,et al.  Cyclic AMP Signaling: A Molecular Determinant of Peripheral Nerve Regeneration , 2014, BioMed research international.

[36]  C. Davies,et al.  GSK356278, a Potent, Selective, Brain-Penetrant Phosphodiesterase 4 Inhibitor That Demonstrates Anxiolytic and Cognition-Enhancing Effects without Inducing Side Effects in Preclinical Species , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[37]  Jane S. Paulsen,et al.  Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.

[38]  David Fox,et al.  Structural basis for the design of selective phosphodiesterase 4B inhibitors. , 2014, Cellular signalling.

[39]  O. Baud,et al.  Sildenafil Mediates Blood-Flow Redistribution and Neuroprotection After Neonatal Hypoxia-Ischemia , 2014, Stroke.

[40]  O. Baud,et al.  Inhaled NO prevents hyperoxia-induced white matter damage in neonatal rats , 2014, Experimental Neurology.

[41]  E. Fedele,et al.  Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D , 2014, Neuropharmacology.

[42]  S. Endo,et al.  Cilostazol improves hippocampus-dependent long-term memory in mice , 2014, Psychopharmacology.

[43]  Ana Martínez,et al.  Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. , 2014, ACS chemical neuroscience.

[44]  Neelima Khairatkar-Joshi,et al.  Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[45]  K. Bacallao,et al.  Opposing Roles of pka and epac in the cAMP-Dependent Regulation of Schwann Cell Proliferation and Differentiation , 2013, PloS one.

[46]  Zhong-Zhen Zhou,et al.  Chlorbipram: a novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer. , 2013, European journal of pharmacology.

[47]  D. Pearse,et al.  Combining Neurotrophin-Transduced Schwann Cells and Rolipram to Promote Functional Recovery from Subacute Spinal Cord Injury , 2013, Cell transplantation.

[48]  A. West,et al.  Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition. , 2013, Basal ganglia.

[49]  D. Wallace,et al.  Subcutaneous daidzein administration enhances recovery of skilled ladder rung walking performance following stroke in rats , 2013, Behavioural Brain Research.

[50]  A. Ballester,et al.  Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis , 2013, British journal of pharmacology.

[51]  A. Geerts,et al.  Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter cell lines. , 2013, Molecular pharmaceutics.

[52]  A. Giralt,et al.  Regulation of Hippocampal cGMP Levels as a Candidate to Treat Cognitive Deficits in Huntington’s Disease , 2013, PloS one.

[53]  I. Ferrer,et al.  Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease , 2013, Neurobiology of Aging.

[54]  S. Morris,et al.  Shaping the Murine Macrophage Phenotype: IL-4 and Cyclic AMP Synergistically Activate the Arginase I Promoter , 2013, The Journal of Immunology.

[55]  K. Malpass Multiple sclerosis: Regenerative therapies for MS—hope on the horizon , 2013, Nature Reviews Neurology.

[56]  A. Giralt,et al.  PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model , 2013, Hippocampus.

[57]  R. Morimoto,et al.  Huntington's disease: underlying molecular mechanisms and emerging concepts. , 2013, Trends in biochemical sciences.

[58]  Ana Martínez,et al.  Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival , 2013, Cellular and Molecular Life Sciences.

[59]  M. Filbin,et al.  Rolipram promotes functional recovery after contusive thoracic spinal cord injury in rats , 2013, Behavioural Brain Research.

[60]  M. Fehlings,et al.  Emerging therapies for acute traumatic spinal cord injury , 2013, Canadian Medical Association Journal.

[61]  E. Karran,et al.  Corrigendum to “Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues” [Neuropharmacology 59 (2010) 367–374] , 2013, Neuropharmacology.

[62]  M. Rusnak,et al.  Traumatic brain injury: Giving voice to a silent epidemic , 2013, Nature Reviews Neurology.

[63]  Xiao Lu,et al.  Identification of Novel Phosphodiesterase-4D Inhibitors Prescreened by Molecular Dynamics-Augmented Modeling and Validated by Bioassay , 2013, J. Chem. Inf. Model..

[64]  Y. Kang,et al.  Age-dependent alterations in cAMP signaling contribute to synaptic plasticity deficits following traumatic brain injury , 2013, Neuroscience.

[65]  N. Plesnila,et al.  Inhaled Nitric Oxide Reduces Secondary Brain Damage after Traumatic Brain Injury in Mice , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[66]  A. Sierksma,et al.  Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease , 2013, Neuropharmacology.

[67]  J. Lanciego,et al.  Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD , 2013, Neuropharmacology.

[68]  P. New,et al.  Global maps of non-traumatic spinal cord injury epidemiology: towards a living data repository , 2013, Spinal Cord.

[69]  C. Atkins,et al.  Effects of early rolipram treatment on histopathological outcome after controlled cortical impact injury in mice , 2013, Neuroscience Letters.

[70]  T. Hage,et al.  Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801 , 2013, Behavioural Brain Research.

[71]  Paul Enright,et al.  Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts , 2012, BMJ Open.

[72]  Alberto Lleó,et al.  Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease , 2012, Acta Neuropathologica.

[73]  H. Bramlett,et al.  Proinflammatory cytokine regulation of cyclic AMP‐phosphodiesterase 4 signaling in microglia in vitro and following CNS injury , 2012, Glia.

[74]  R. Franco,et al.  Phosphodiesterases as therapeutic targets for Alzheimer's disease. , 2012, ACS chemical neuroscience.

[75]  D. Abo-Elmatty,et al.  Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats , 2012, Indian journal of pharmacology.

[76]  P. Gressens,et al.  Inhaled Nitric Oxide Reduces Brain Damage by Collateral Recruitment in a Neonatal Stroke Model , 2012, Stroke.

[77]  Jeih-San Liow,et al.  Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder , 2012, Biological Psychiatry.

[78]  J. O'Donnell,et al.  Evidence for Global Reduction in Brain Cyclic Adenosine Monophosphate Signaling in Depression , 2012, Biological Psychiatry.

[79]  Samik Patel,et al.  The Therapeutic Profile of Rolipram, PDE Target and Mechanism of Action as a Neuroprotectant following Spinal Cord Injury , 2012, PloS one.

[80]  C. Stratakis Cyclic AMP, Protein Kinase A, and Phosphodiesterases: Proceedings of an International Workshop , 2012, Hormone and Metabolic Research.

[81]  F. Menniti,et al.  Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. , 2012, Journal of medicinal chemistry.

[82]  N. Plesnila,et al.  Nitric Oxide: Considerations for the Treatment of Ischemic Stroke , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[83]  Eric R Kandel,et al.  The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB , 2012, Molecular Brain.

[84]  S. Blumenthal Earl Sutherland (1915-1975) and the Discovery of Cyclic AMP , 2012, Perspectives in biology and medicine.

[85]  Jason J. Corneveaux,et al.  A genome-wide scan for common variants affecting the rate of age-related cognitive decline , 2012, Neurobiology of Aging.

[86]  Johannes Boltze,et al.  Inhalation of Nitric Oxide Prevents Ischemic Brain Damage in Experimental Stroke by Selective Dilatation of Collateral Arterioles , 2012, Circulation research.

[87]  D. Manahan‐Vaughan,et al.  PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis , 2012, Translational Psychiatry.

[88]  Jordan F Baye Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. , 2012, P & T : a peer-reviewed journal for formulary management.

[89]  E. Palazidou The neurobiology of depression. , 2012, British medical bulletin.

[90]  P. Sharma,et al.  Neuroprotective effect of Vinpocetine against 3- NP Induced reduction of body weight and oxidative stress in Rats , 2012 .

[91]  Pal Pacher,et al.  Adenosine promotes alternative macrophage activation via A2A and A2B receptors , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[92]  C. C. Filgueiras,et al.  Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder. , 2011, Drug and alcohol dependence.

[93]  R. Franco,et al.  Sildenafil restores cognitive function without affecting β‐amyloid burden in a mouse model of Alzheimer's disease , 2011, British journal of pharmacology.

[94]  E. Fedele,et al.  GEBR‐7b, a novel PDE4D selective inhibitor that improves memory in rodents at non‐emetic doses , 2011, British journal of pharmacology.

[95]  Lynn A. Hyde,et al.  The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents , 2011, Neuropharmacology.

[96]  A. Giralt,et al.  Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. , 2011, Human molecular genetics.

[97]  D. Pearse,et al.  A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury. , 2011, Journal of neurotrauma.

[98]  M. Tresguerres,et al.  Intracellular cAMP signaling by soluble adenylyl cyclase. , 2011, Kidney international.

[99]  K. Taskén,et al.  Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells. , 2011, Cellular signalling.

[100]  K. Rabe Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease , 2011, British journal of pharmacology.

[101]  G. Doronzo,et al.  Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: influence of insulin resistance and oxidative stress. , 2011, Atherosclerosis.

[102]  J. Corbin,et al.  Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. , 2011, Physiological reviews.

[103]  M. Keshavan,et al.  Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse , 2011, Schizophrenia Research.

[104]  C. Pérez,et al.  Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease , 2011, PloS one.

[105]  Han-Ting Zhang,et al.  Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats , 2011, Metabolic Brain Disease.

[106]  Alan J. Thomas,et al.  Neuropathological correlates of late-life depression in older people , 2011, British Journal of Psychiatry.

[107]  P. Calabresi,et al.  Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. , 2011, Brain : a journal of neurology.

[108]  E. Mazzon,et al.  PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury , 2011, PloS one.

[109]  J. O'Donnell,et al.  Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP Signaling , 2011, The Journal of Neuroscience.

[110]  F. Colbatzky,et al.  Inhibition of cyclooxygenase‐2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats , 2011, British journal of pharmacology.

[111]  Ann Wu,et al.  A preconditioning nerve lesion inhibits mechanical pain hypersensitivity following subsequent neuropathic injury , 2011, Molecular pain.

[112]  T. Ferguson,et al.  Extrinsic and intrinsic determinants of nerve regeneration , 2011, Journal of tissue engineering.

[113]  M. Hiramatsu,et al.  Cilostazol prevents amyloid β peptide25‐35‐induced memory impairment and oxidative stress in mice , 2010, British journal of pharmacology.

[114]  R. Young,et al.  Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. , 2010, Bioorganic & medicinal chemistry letters.

[115]  G. Bernardi,et al.  Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease , 2010, PloS one.

[116]  G. Anand,et al.  Phosphodiesterases Catalyze Hydrolysis of cAMP-bound to Regulatory Subunit of Protein Kinase A and Mediate Signal Termination* , 2010, Molecular & Cellular Proteomics.

[117]  A. Nishi,et al.  Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. , 2010, Journal of pharmacological sciences.

[118]  M. Houslay,et al.  Cyclic AMP Controls mTOR through Regulation of the Dynamic Interaction between Rheb and Phosphodiesterase 4D , 2010, Molecular and Cellular Biology.

[119]  M. Keshavan,et al.  Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future , 2010, Schizophrenia Research.

[120]  A. Hatzelmann,et al.  The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. , 2010, Pulmonary pharmacology & therapeutics.

[121]  J. Jordán,et al.  Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF , 2010, Neurobiology of Disease.

[122]  J. Strosznajder,et al.  Cyclic GMP and Nitric Oxide Synthase in Aging and Alzheimer's Disease , 2010, Molecular Neurobiology.

[123]  F. Hofmann,et al.  Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes , 2010, Proceedings of the National Academy of Sciences.

[124]  C. Lugnier,et al.  Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. , 2010, Current pharmaceutical design.

[125]  M. Houslay Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.

[126]  J. Bryson,et al.  A Large-Scale Chemical Screen for Regulators of the Arginase 1 Promoter Identifies the Soy Isoflavone Daidzeinas a Clinically Approved Small Molecule That Can Promote Neuronal Protection or Regeneration via a cAMP-Independent Pathway , 2010, The Journal of Neuroscience.

[127]  J. Bos,et al.  Epac: defining a new mechanism for cAMP action. , 2010, Annual review of pharmacology and toxicology.

[128]  Timothy Hagen,et al.  Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety , 2010, Nature Biotechnology.

[129]  D. Schadendorf,et al.  cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells , 2009, Cellular and Molecular Life Sciences.

[130]  Tony Wyss-Coray,et al.  Immune Activation in Brain Aging and Neurodegeneration: Too Much or Too Little? , 2009, Neuron.

[131]  Vivek Sharma,et al.  Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine -- a PDE1 inhibitor. , 2009, European journal of pharmacology.

[132]  M. Munder Arginase: an emerging key player in the mammalian immune system , 2009, British journal of pharmacology.

[133]  S. P. Bhatnagar,et al.  A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. , 2009, Bioorganic & medicinal chemistry.

[134]  J. Bryson,et al.  Increased Synthesis of Spermidine as a Result of Upregulation of Arginase I Promotes Axonal Regeneration in Culture and In Vivo , 2009, The Journal of Neuroscience.

[135]  Spiros Liras,et al.  Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. , 2009, Journal of medicinal chemistry.

[136]  F. Menniti,et al.  PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. , 2009, Current opinion in drug discovery & development.

[137]  A. Palmeri,et al.  Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-β Load in an Alzheimer's Disease Mouse Model , 2009, The Journal of Neuroscience.

[138]  J. John Mann,et al.  Antidepressants increase neural progenitor cells in the human hippocampus , 2009, Neuropsychopharmacology.

[139]  Han-Ting Zhang Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. , 2009, Current pharmaceutical design.

[140]  M. Wong,et al.  Association of PDE11A global haplotype with major depression and antidepressant drug response , 2009, Neuropsychiatric disease and treatment.

[141]  J. Bos,et al.  Direct Spatial Control of Epac1 by Cyclic AMP , 2009, Molecular and Cellular Biology.

[142]  G. Bernardi,et al.  Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington’s disease , 2009, The European journal of neuroscience.

[143]  A. West,et al.  Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation , 2009, Journal of Pharmacology and Experimental Therapeutics.

[144]  H. Daniel,et al.  Epac mediates PACAP‐dependent long‐term depression in the hippocampus , 2009, The Journal of physiology.

[145]  Takaichi Fukuda,et al.  Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum , 2008, The Journal of Neuroscience.

[146]  A. Dolga,et al.  Neuronal AKAP150 coordinates PKA and Epac-mediated PKB/Akt phosphorylation. , 2008, Cellular signalling.

[147]  J. Zhu,et al.  Epac signaling is required for hippocampus-dependent memory retrieval , 2008, Proceedings of the National Academy of Sciences.

[148]  E. Neher,et al.  Application of an Epac Activator Enhances Neurotransmitter Release at Excitatory Central Synapses , 2008, The Journal of Neuroscience.

[149]  Andrew J. Murray,et al.  Epac mediates cyclic AMP-dependent axon growth, guidance and regeneration , 2008, Molecular and Cellular Neuroscience.

[150]  A. Blokland,et al.  Enhanced long‐term potentiation and impaired learning in phosphodiesterase 4D‐knockout (PDE4D−/−) mice , 2008, The European journal of neuroscience.

[151]  D. Cabrol,et al.  The PDE4 Inhibitor Rolipram Prevents NF-κB Binding Activity and Proinflammatory Cytokine Release in Human Chorionic Cells1 , 2008, The Journal of Immunology.

[152]  M. Keshavan,et al.  Neurobiology of the early course of schizophrenia , 2008, Expert review of neurotherapeutics.

[153]  J. Strosznajder,et al.  The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging , 2008, Brain Research.

[154]  D. Magnuson,et al.  Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury , 2008, Neuroscience Letters.

[155]  Eric Klann,et al.  Activation of exchange protein activated by cyclic-AMP enhances long-lasting synaptic potentiation in the hippocampus. , 2008, Learning & memory.

[156]  J. O'Donnell,et al.  Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B) , 2008, Neuropsychopharmacology.

[157]  G. Bernardi,et al.  Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease , 2008, Neurobiology of Disease.

[158]  R. D. Williams,et al.  Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia , 2008, Journal of Pharmacology and Experimental Therapeutics.

[159]  M. Beal,et al.  Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV , 2008, Experimental Neurology.

[160]  J. Corbin,et al.  Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function , 2008, International Journal of Impotence Research.

[161]  H. Yeh,et al.  Synaptic Function for the Nogo-66 Receptor NgR1: Regulation of Dendritic Spine Morphology and Activity-Dependent Synaptic Strength , 2008, The Journal of Neuroscience.

[162]  D. Aronoff,et al.  Cyclic AMP: master regulator of innate immune cell function. , 2008, American journal of respiratory cell and molecular biology.

[163]  M. Filbin,et al.  The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury , 2008, Experimental Neurology.

[164]  S. Roscioni,et al.  Epac: effectors and biological functions , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[165]  H. Ke,et al.  Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil , 2008, Molecular Pharmacology.

[166]  J. Kleim,et al.  A Novel Phosphodiesterase Type 4 Inhibitor, HT-0712, Enhances Rehabilitation-Dependent Motor Recovery and Cortical Reorganization After Focal Cortical Ischemia , 2007, Neurorehabilitation and neural repair.

[167]  H. Bramlett,et al.  Modulation of the cAMP signaling pathway after traumatic brain injury , 2007, Experimental Neurology.

[168]  L. Fabbri,et al.  Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[169]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.

[170]  L. Zhang,et al.  L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. , 2007, Biochemical pharmacology.

[171]  G. Mengod,et al.  Expression of the cGMP‐specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains , 2007, The European journal of neuroscience.

[172]  Changping Yao,et al.  Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation , 2007, Neuroscience Letters.

[173]  K. Jakobs,et al.  Epac and the cardiovascular system. , 2007, Current opinion in pharmacology.

[174]  V. Yong,et al.  Characterization of the Early Neuroinflammation After Spinal Cord Injury in Mice , 2007, Journal of neuropathology and experimental neurology.

[175]  Sydney Brenner,et al.  Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease. , 2007, Archives of neurology.

[176]  J. Bockaert,et al.  Exchange protein activated by cAMP (Epac) mediates cAMP activation of p38 MAPK and modulation of Ca2+-dependent K+ channels in cerebellar neurons , 2007, Proceedings of the National Academy of Sciences.

[177]  G. Bernardi,et al.  Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity , 2007, Neurobiology of Disease.

[178]  S. Karmakar,et al.  Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate , 2006, Neuroscience.

[179]  J. Bos,et al.  Epac proteins: multi-purpose cAMP targets. , 2006, Trends in biochemical sciences.

[180]  J. Mancini,et al.  Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. , 2006, Current medicinal chemistry.

[181]  R. Cantor,et al.  Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response , 2006, Proceedings of the National Academy of Sciences.

[182]  C. Steegborn,et al.  Molecular details of cAMP generation in mammalian cells: a tale of two systems. , 2006, Journal of molecular biology.

[183]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[184]  D. Rosskopf,et al.  Cyclic AMP-dependent and Epac-mediated Activation of R-Ras by G Protein-coupled Receptors Leads to Phospholipase D Stimulation* , 2006, Journal of Biological Chemistry.

[185]  M. Giembycz An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. , 2006, British journal of clinical pharmacology.

[186]  S. Døskeland,et al.  Epac1 and cAMP-dependent Protein Kinase Holoenzyme Have Similar cAMP Affinity, but Their cAMP Domains Have Distinct Structural Features and Cyclic Nucleotide Recognition* , 2006, Journal of Biological Chemistry.

[187]  T. Michaeli,et al.  PDE7A1, a cAMP-specific Phosphodiesterase, Inhibits cAMP-dependent Protein Kinase by a Direct Interaction with C* , 2006, Journal of Biological Chemistry.

[188]  R. B. Hart,et al.  The Cytokine Interleukin-6 Is Sufficient But Not Necessary to Mimic the Peripheral Conditioning Lesion Effect on Axonal Growth , 2006, The Journal of Neuroscience.

[189]  R. D. Williams,et al.  Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase , 2006, Neuroscience.

[190]  K. Hsu,et al.  Presynaptic Mechanism Underlying cAMP-Induced Synaptic Potentiation in Medial Prefrontal Cortex Pyramidal Neurons , 2006, Molecular Pharmacology.

[191]  K. Sansam Controversies in the management of traumatic spinal cord injury. , 2006, Clinical medicine.

[192]  A. Blokland,et al.  Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action , 2006, Neurobiology of Learning and Memory.

[193]  J. Schultz,et al.  cAMP Is a Ligand for the Tandem GAF Domain of Human Phosphodiesterase 10 and cGMP for the Tandem GAF Domain of Phosphodiesterase 11* , 2006, Journal of Biological Chemistry.

[194]  R. Biondi,et al.  Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells. , 2005, Molecular biology of the cell.

[195]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[196]  M. Houslay,et al.  In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. , 2005, Cellular signalling.

[197]  R. H. Cote,et al.  Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. , 2005, Investigative ophthalmology & visual science.

[198]  E. Bateman,et al.  Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial , 2005, The Lancet.

[199]  Yin-ming Zeng,et al.  Activation of ERK/CREB pathway in spinal cord contributes to chronic constrictive injury-induced neuropathic pain in rats , 2005, Acta Pharmacologica Sinica.

[200]  K. Vranizan,et al.  Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[201]  J. Langlois,et al.  Traumatic Brain Injury Hospitalizations Among American Indians/Alaska Natives , 2005, The Journal of head trauma rehabilitation.

[202]  H. Robertson,et al.  Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington′s disease transgenic mice prior to the onset of motor symptoms , 2004, Neuroscience.

[203]  M. Pruniaux,et al.  Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation1 , 2004, The Journal of Immunology.

[204]  O. Vitolo,et al.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. , 2004, The Journal of clinical investigation.

[205]  K. So,et al.  Involvement of cAMP in neuronal survival and axonal regeneration , 2004, Anatomical science international.

[206]  D. Ingram,et al.  Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats , 2004, Pharmacology Biochemistry and Behavior.

[207]  Eric R. Kandel,et al.  Activated CREB Is Sufficient to Overcome Inhibitors in Myelin and Promote Spinal Axon Regeneration In Vivo , 2004, Neuron.

[208]  R. Ratan,et al.  Novel roles for arginase in cell survival, regeneration, and translation in the central nervous system. , 2004, The Journal of nutrition.

[209]  W. D. Dietrich,et al.  Tumor Necrosis Factor &agr; Expression and Protein Levels after Fluid Percussion Injury in Rats: The Effect of Injury Severity and Brain Temperature , 2004, Neurosurgery.

[210]  E. Vandenbussche,et al.  Cognitive changes in patients with Huntington’s disease (HD) and asymptomatic carriers of the HD mutation , 2004, Journal of Neurology.

[211]  M. Fehlings,et al.  The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. , 2004, Journal of neurotrauma.

[212]  Kam Y. J. Zhang,et al.  A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. , 2004, Molecular cell.

[213]  M. Tuszynski,et al.  Combinatorial Therapy with Neurotrophins and cAMP Promotes Axonal Regeneration beyond Sites of Spinal Cord Injury , 2004, The Journal of Neuroscience.

[214]  M. Filbin,et al.  The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[215]  M. Filbin,et al.  cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury , 2004, Nature Medicine.

[216]  J. Kotera,et al.  Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP‐dependent protein kinase/cyclic AMP‐response element binding protein pathway in primary striatal neurons , 2004, Journal of neurochemistry.

[217]  R. Duman,et al.  Activation of cAMP Signaling Facilitates the Morphological Maturation of Newborn Neurons in Adult Hippocampus , 2004, The Journal of Neuroscience.

[218]  M. Filbin,et al.  A role for cAMP in regeneration of the adult mammalian CNS , 2004, Journal of anatomy.

[219]  R. Bullock,et al.  Clinical Trials in Traumatic Brain Injury: Lessons for the Future , 2004, Journal of neurosurgical anesthesiology.

[220]  W. Mellado,et al.  Neurotrophins Elevate cAMP to Reach a Threshold Required to Overcome Inhibition by MAG through Extracellular Signal-Regulated Kinase-Dependent Inhibition of Phosphodiesterase , 2003, The Journal of Neuroscience.

[221]  R. Ricciardi,et al.  Phosphorylation of Serine 337 of NF-κB p50 Is Critical for DNA Binding* , 2003, Journal of Biological Chemistry.

[222]  A. Arnsten,et al.  Dysregulation of Protein Kinase A Signaling in the Aged Prefrontal Cortex New Strategy for Treating Age-Related Cognitive Decline , 2003, Neuron.

[223]  J. Eisenach,et al.  Intrathecal injection of cAMP response element binding protein (CREB) antisense oligonucleotide attenuates tactile allodynia caused by partial sciatic nerve ligation , 2003, Brain Research.

[224]  D. Umetsu,et al.  PDE4D plays a critical role in the control of airway smooth muscle contraction , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[225]  Pierre Voisin,et al.  A proline-rich domain in the gamma subunit of phosphodiesterase 6 mediates interaction with SH3-containing proteins. , 2003, Molecular vision.

[226]  S. Døskeland,et al.  cAMP Analog Mapping of Epac1 and cAMP Kinase , 2003, Journal of Biological Chemistry.

[227]  D. Hochbaum,et al.  Activation of JNK by Epac Is Independent of Its Activity as a Rap Guanine Nucleotide Exchanger* , 2003, Journal of Biological Chemistry.

[228]  J. Bos Epac: a new cAMP target and new avenues in cAMP research , 2003, Nature Reviews Molecular Cell Biology.

[229]  H. Kraemer,et al.  Untreated depression and hippocampal volume loss. , 2003, The American journal of psychiatry.

[230]  J. Palacios,et al.  Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer’s disease brains examined by in situ hybridization , 2003, Experimental Neurology.

[231]  S. Døskeland,et al.  cAMP effector mechanisms. Novel twists for an ‘old’ signaling system , 2003, FEBS letters.

[232]  P. Soulard,et al.  Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. , 2003, International immunology.

[233]  N. Sakurai,et al.  Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. , 2003, Cellular signalling.

[234]  G. Mengod,et al.  cAMP-specific phosphodiesterases expression in Alzheimer's disease brains , 2003 .

[235]  M. Houslay,et al.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. , 2003, The Biochemical journal.

[236]  R. Segal,et al.  p75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp , 2002, Nature.

[237]  M. Conti,et al.  Dimerization of the Type 4 cAMP-specific Phosphodiesterases Is Mediated by the Upstream Conserved Regions (UCRs)* , 2002, The Journal of Biological Chemistry.

[238]  S. Jin,et al.  Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. , 2002, The Journal of clinical investigation.

[239]  J. O'Donnell,et al.  Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme , 2002, Neuropsychopharmacology.

[240]  C. Webster,et al.  cAMP inhibits bile acid-induced apoptosis by blocking caspase activation and cytochrome c release. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[241]  J. Beavo,et al.  Cyclic nucleotide research — still expanding after half a century , 2002, Nature Reviews Molecular Cell Biology.

[242]  P. Thibault,et al.  Oligodendrocyte‐myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth , 2002, Journal of neurochemistry.

[243]  W. Mellado,et al.  Arginase I and Polyamines Act Downstream from Cyclic AMP in Overcoming Inhibition of Axonal Growth MAG and Myelin In Vitro , 2002, Neuron.

[244]  W. D. Dietrich,et al.  Interleukin-1β Messenger Ribonucleic Acid and Protein Levels after Fluid-Percussion Brain Injury in Rats: Importance of Injury Severity and Brain Temperature. , 2002, Neurosurgery.

[245]  Ian McPhee,et al.  Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A‐mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1) , 2002, British journal of pharmacology.

[246]  R. Sunahara,et al.  Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. , 2002, Molecular interventions.

[247]  M. Morganti-Kossmann,et al.  Inflammatory response in acute traumatic brain injury: a double-edged sword , 2002, Current opinion in critical care.

[248]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[249]  S. Takeo,et al.  Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism‐induced defects in memory function and cerebral cyclic AMP signal transduction system in rats , 2002, British journal of pharmacology.

[250]  K. Jin,et al.  MEK and ERK protect hypoxic cortical neurons via phosphorylation of Bad , 2002, Journal of neurochemistry.

[251]  M. Billah,et al.  Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. , 2001, Gene.

[252]  Marc Montminy,et al.  Transcriptional regulation by the phosphorylation-dependent factor CREB , 2001, Nature Reviews Molecular Cell Biology.

[253]  L. Levin,et al.  Bicarbonate-regulated soluble adenylyl cyclase. , 2001, JOP : Journal of the pancreas.

[254]  S. R. Datta,et al.  Transcription-dependent and -independent control of neuronal survival by the PI3K–Akt signaling pathway , 2001, Current Opinion in Neurobiology.

[255]  A. Fournier,et al.  Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration , 2001, Nature.

[256]  John Calvin Reed,et al.  MEK/ERK signaling pathway regulates the expression of Bcl‐2, Bcl‐XL, and Mcl‐1 and promotes survival of human pancreatic cancer cells , 2000, Journal of cellular biochemistry.

[257]  G. Baillie,et al.  Sub‐family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP‐specific phosphodiesterases , 2000, British journal of pharmacology.

[258]  Y. Zhao,et al.  Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. , 2000, Science.

[259]  G. Baillie,et al.  ERK2 Mitogen-activated Protein Kinase Binding, Phosphorylation, and Regulation of the PDE4D cAMP-specific Phosphodiesterases , 2000, The Journal of Biological Chemistry.

[260]  R. Hicks,et al.  Local neutrophil influx following lateral fluid-percussion brain injury in rats is associated with accumulation of complement activation fragments of the third component (C3) of the complement system , 2000, Journal of Neuroimmunology.

[261]  B. Boulanger,et al.  Beta adrenoceptor regulation of macrophage arginase activity. , 2000, Surgery.

[262]  R. Zucker,et al.  Enhancement of synaptic transmission by cyclic AMP modulation of presynaptic Ih channels , 2000, Nature Neuroscience.

[263]  Fumio Nakamura,et al.  Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein , 2000, Nature.

[264]  Martin E. Schwab,et al.  Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1 , 2000, Nature.

[265]  R. Prinjha,et al.  Neurobiology: Inhibitor of neurite outgrowth in humans , 2000, Nature.

[266]  S. Kish,et al.  Reduced adenylyl cyclase immunolabeling and activity in postmortem temporal cortex of depressed suicide victims. , 1999, Journal of affective disorders.

[267]  S. R. Datta,et al.  Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. , 1999, Science.

[268]  N. Leclerc,et al.  Inactivation of Rho Signaling Pathway Promotes CNS Axon Regeneration , 1999, The Journal of Neuroscience.

[269]  F. Hayashi,et al.  Suppression of GTP/T alpha-dependent activation of cGMP phosphodiesterase by ADP-ribosylation by its gamma subunit in amphibian rod photoreceptor membranes. , 1999, Biochemistry.

[270]  G. Baillie,et al.  The MAP kinase ERK2 inhibits the cyclic AMP‐specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579 , 1999, The EMBO journal.

[271]  F. D. Tattersall,et al.  Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret , 1999, Neuropharmacology.

[272]  E. Kandel,et al.  Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[273]  A. Wittinghofer,et al.  Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP , 1998, Nature.

[274]  G. MacQueen,et al.  Increased temporal cortex CREB concentrations and antidepressant treatment in major depression , 1998, The Lancet.

[275]  M. Hanson,et al.  Depolarization and cAMP Elevation Rapidly Recruit TrkB to the Plasma Membrane of CNS Neurons , 1998, Neuron.

[276]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[277]  L. Lim,et al.  cAMP-induced Morphological Changes Are Counteracted by the Activated RhoA Small GTPase and the Rho Kinase ROKα* , 1998, The Journal of Biological Chemistry.

[278]  M. Houslay,et al.  cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. , 1998, The Biochemical journal.

[279]  B. Bregman,et al.  Transplants and Neurotrophic Factors Prevent Atrophy of Mature CNS Neurons after Spinal Cord Injury , 1998, Experimental Neurology.

[280]  K. Sluka Activation of the cAMP transduction cascade contributes to the mechanical hyperalgesia and allodynia induced by intradermal injection of capsaicin , 1997, British journal of pharmacology.

[281]  A. Sawa,et al.  Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons. , 1997, Japanese journal of pharmacology.

[282]  M. Ohashi,et al.  Residues within the polycationic region of cGMP phosphodiesterase gamma subunit crucial for the interaction with transducin alpha subunit. Identification by endogenous ADP-ribosylation and site-directed mutagenesis. , 1997, The Journal of biological chemistry.

[283]  N. Artemyev,et al.  The γ Subunit of Rod cGMP-Phosphodiesterase Blocks the Enzyme Catalytic Site* , 1997, The Journal of Biological Chemistry.

[284]  M. Teixeira,et al.  Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? , 1997, Trends in pharmacological sciences.

[285]  P. Peterson,et al.  CYTOKINE-MEDIATED NEURONAL APOPTOSIS , 1997, Neurochemistry International.

[286]  T. Yamamoto,et al.  Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. , 1997, European journal of pharmacology.

[287]  T. Gordon,et al.  The cellular and molecular basis of peripheral nerve regeneration , 1997, Molecular Neurobiology.

[288]  A. Rajput,et al.  Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. , 1996, Life Science.

[289]  T. Robbins,et al.  Executive and mnemonic functions in early Huntington's disease. , 1996, Brain : a journal of neurology.

[290]  D. Wallach,et al.  Inhibition of Tumor Necrosis Factor Alpha (TNFα) Activity in Rat Brain is Associated with Cerebroprotection after Closed Head Injury , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[291]  J. Csernansky,et al.  Hippocampal atrophy in recurrent major depression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[292]  P. Young,et al.  Experimental brain injury induces differential expression of tumor necrosis factor-alpha mRNA in the CNS. , 1996, Brain research. Molecular brain research.

[293]  R. Stancou,et al.  Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. , 1996, The EMBO journal.

[294]  P. Hulley,et al.  Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra Neurons In Vivo , 1995, The European journal of neuroscience.

[295]  R J Heaslip,et al.  Emetic, central nervous system, and pulmonary activities of rolipram in the dog. , 1995, European journal of pharmacology.

[296]  M. Conti,et al.  Phosphorylation and Activation of a cAMP-specific Phosphodiesterase by the cAMP-dependent Protein Kinase , 1995, The Journal of Biological Chemistry.

[297]  E. Degerman,et al.  Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. , 1995, Archives of biochemistry and biophysics.

[298]  K. Hashimoto,et al.  Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. , 1995, European journal of pharmacology.

[299]  E. Siemers,et al.  Cognitive scores in carriers of huntington's disease gene compared to noncarriers , 1995, Annals of neurology.

[300]  D. Ferrari,et al.  Activation of microglial cells by β-amyloid protein and interferon-γ , 1995, Nature.

[301]  M. Greenberg,et al.  Serine 133-Phosphorylated CREB Induces Transcription via a Cooperative Mechanism That May Confer Specificity to Neurotrophin Signals , 1995, Molecular and Cellular Neuroscience.

[302]  D. Yarnall,et al.  Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. , 1995, The Journal of pharmacology and experimental therapeutics.

[303]  M. Modolell,et al.  Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. , 1995, Biochemical and biophysical research communications.

[304]  L. Mckerracher,et al.  Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth , 1994, Neuron.

[305]  M. Filbin,et al.  A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration , 1994, Neuron.

[306]  W. K. Sonnenburg,et al.  Phosphorylation of the 61-kDa calmodulin-stimulated cyclic nucleotide phosphodiesterase at serine 120 reduces its affinity for calmodulin. , 1994, Biochemistry.

[307]  G. B. Wisely,et al.  NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. , 1994, Journal of immunology.

[308]  JW Polli,et al.  Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[309]  J. Marcusson,et al.  Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims , 1994, Brain Research.

[310]  C. Saper,et al.  Distribution and characterization of tumor necrosis factor‐α‐like immunoreactivity in the murine central nervous system , 1993 .

[311]  M. Wigler,et al.  A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs , 1993, Molecular and cellular biology.

[312]  P. Barie,et al.  Human astrocyte production of tumour necrosis factor-α, interleukin-1β, and interleukin-6 following exposure to lipopolysaccharide endotoxin , 1993 .

[313]  J. Bénavidès,et al.  Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand , 1993, Journal of Neuroimmunology.

[314]  M. Conti,et al.  Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. , 1992, The Journal of biological chemistry.

[315]  J. Corbin,et al.  A phenylalanine in peptide substrates provides for selectivity between cGMP- and cAMP-dependent protein kinases. , 1992, The Journal of biological chemistry.

[316]  L. Gaal,et al.  Effect of different subtypes of cognition enhancers on long-term potentiation in the rat dentate gyrus in vivo. , 1992, European journal of pharmacology.

[317]  J. Silver,et al.  Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[318]  C H Tator,et al.  Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. , 1991, Journal of neurosurgery.

[319]  T. Soderling,et al.  Regulation of Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase by the autophosphorylated form of Ca2+/calmodulin-dependent protein kinase II. , 1989, The Journal of biological chemistry.

[320]  M. Montminy,et al.  Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene , 1987, Nature.

[321]  V. Denoble Vinpocetine enhances retrieval of a step-through passive avoidance response in rats , 1987, Pharmacology Biochemistry and Behavior.

[322]  R. Butcher,et al.  Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. , 1962, The Journal of biological chemistry.

[323]  D. Ingram,et al.  Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline. , 2014, NeuroRehabilitation.

[324]  M. Gurney,et al.  Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer’s Disease , 2014, Neurotherapeutics.

[325]  M. A. Moro,et al.  Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. , 2012, European journal of medicinal chemistry.

[326]  K. Rabe,et al.  The Efficacy and Safety of Cilomilast in COPD , 2012, Drugs.

[327]  M. Houslay,et al.  Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. , 2011, Handbook of experimental pharmacology.

[328]  J. O'Donnell,et al.  Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. , 2011, Handbook of experimental pharmacology.

[329]  T. Kleppisch Phosphodiesterases in the central nervous system. , 2009, Handbook of experimental pharmacology.

[330]  S. Strittmatter,et al.  Axon regeneration in the peripheral and central nervous systems. , 2009, Results and problems in cell differentiation.

[331]  J. Siuciak The Role of Phosphodiesterases in Schizophrenia , 2008, CNS drugs.

[332]  Susan S. Taylor,et al.  Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. , 2008, Biochimica et biophysica acta.

[333]  M. Tymianski,et al.  Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death , 2007, Molecular Neurobiology.

[334]  J. Gies,et al.  Heptahelical and other G-protein-coupled receptors (GPCRs) signaling. , 2006, Current medicinal chemistry.

[335]  R. Cote Cyclic guanosine 5'-monophosphate binding to regulatory GAF domains of photoreceptor phosphodiesterase. , 2005, Methods in molecular biology.

[336]  K. Kinoshita,et al.  The role of inflammatory processes in the pathophysiology and treatment of brain and spinal cord trauma. , 2004, Acta neurochirurgica. Supplement.

[337]  G. Smith,et al.  Peripheral nerve grafts lacking viable Schwann cells fail to support central nervous system axonal regeneration , 2004, Experimental Brain Research.

[338]  S. Gordon Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[339]  Yogesh K. Dwivedi,et al.  [(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims. , 2002, The American journal of psychiatry.

[340]  E. Huang,et al.  Neurotrophins: roles in neuronal development and function. , 2001, Annual review of neuroscience.

[341]  J. Hanoune,et al.  Regulation and role of adenylyl cyclase isoforms. , 2001, Annual review of pharmacology and toxicology.

[342]  E. Degerman,et al.  Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. , 2001, Progress in nucleic acid research and molecular biology.

[343]  L. Staib,et al.  Hippocampal volume reduction in major depression. , 2000, The American journal of psychiatry.

[344]  M. Filbin,et al.  Prior Exposure to Neurotrophins Blocks Inhibition of Axonal Regeneration by MAG and Myelin via a cAMP-Dependent Mechanism , 1999, Neuron.

[345]  J. Habener,et al.  Cyclic AMP signaling and gene regulation. , 1998, Annual review of nutrition.

[346]  M. Houslay,et al.  The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. , 1998, Advances in pharmacology.

[347]  S R Sprang,et al.  G protein mechanisms: insights from structural analysis. , 1997, Annual review of biochemistry.

[348]  Douglas H. Smith,et al.  Temporal and spatial characterization of neuronal injury following lateral fluid-percussion brain injury in the rat , 1996, Acta Neuropathologica.

[349]  Y. Katayama,et al.  Excitatory amino acid release from contused brain tissue into surrounding brain areas. , 1994, Acta neurochirurgica. Supplementum.

[350]  I. Hindmarch,et al.  Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. , 1991, International clinical psychopharmacology.